STOCK TITAN

argenx to Present at Goldman Sachs 46th Annual Global Healthcare Conference

Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
conferences
argenx (Nasdaq: ARGX), a global immunology company focused on severe autoimmune diseases, announced its participation in the Goldman Sachs 46th Annual Global Healthcare Conference. Karl Gubitz, the company's Chief Financial Officer, will engage in a fireside chat on Tuesday, June 10, 2025, at 8:40 AM ET in Miami, FL. The presentation will be accessible via live webcast through the Investors section of argenx's website at argenx.com/investors, with a replay available for approximately 30 days following the event.
argenx (Nasdaq: ARGX), un'azienda globale nel campo dell'immunologia specializzata nelle gravi malattie autoimmuni, ha annunciato la sua partecipazione alla 46ª Conferenza Annuale Globale sulla Sanità di Goldman Sachs. Karl Gubitz, Chief Financial Officer dell'azienda, parteciperà a una chiacchierata informale martedì 10 giugno 2025 alle 8:40 ET a Miami, FL. La presentazione sarà accessibile in diretta streaming tramite la sezione Investitori del sito web di argenx all'indirizzo argenx.com/investors, con una replica disponibile per circa 30 giorni dopo l'evento.
argenx (Nasdaq: ARGX), una compañía global de inmunología centrada en enfermedades autoinmunes graves, anunció su participación en la 46ª Conferencia Anual Global de Salud de Goldman Sachs. Karl Gubitz, director financiero de la empresa, participará en una charla informal el martes 10 de junio de 2025 a las 8:40 AM ET en Miami, FL. La presentación estará disponible en transmisión en vivo a través de la sección de Inversores en el sitio web de argenx en argenx.com/investors, con una repetición accesible aproximadamente durante 30 días después del evento.
argenx(Nasdaq: ARGX)는 중증 자가면역 질환에 집중하는 글로벌 면역학 회사로, 골드만삭스 제46회 연례 글로벌 헬스케어 컨퍼런스에 참여한다고 발표했습니다. 회사의 최고재무책임자(CFO)인 칼 구비츠가 2025년 6월 10일 화요일 오전 8시 40분(동부시간)에 플로리다 마이애미에서 진행되는 비공식 대화에 참여할 예정입니다. 발표는 argenx 웹사이트의 투자자 섹션(argenx.com/investors)을 통해 생중계되며, 행사 종료 후 약 30일간 다시보기 서비스도 제공됩니다.
argenx (Nasdaq : ARGX), une entreprise mondiale spécialisée en immunologie axée sur les maladies auto-immunes sévères, a annoncé sa participation à la 46e Conférence annuelle mondiale sur la santé de Goldman Sachs. Karl Gubitz, directeur financier de la société, participera à une discussion informelle le mardi 10 juin 2025 à 8h40 ET à Miami, FL. La présentation sera accessible en webdiffusion en direct via la section Investisseurs du site web d'argenx à l'adresse argenx.com/investors, avec une rediffusion disponible pendant environ 30 jours après l'événement.
argenx (Nasdaq: ARGX), ein weltweit tätiges Immunologie-Unternehmen mit Schwerpunkt auf schweren Autoimmunerkrankungen, gab seine Teilnahme an der 46. jährlichen Global Healthcare Conference von Goldman Sachs bekannt. Karl Gubitz, der Finanzvorstand des Unternehmens, wird am Dienstag, den 10. Juni 2025, um 8:40 Uhr ET in Miami, FL, an einem informellen Gespräch teilnehmen. Die Präsentation wird live über einen Webcast im Investorenbereich der argenx-Website unter argenx.com/investors verfügbar sein, mit einer Wiederholung, die etwa 30 Tage nach der Veranstaltung abrufbar ist.
Positive
  • None.
Negative
  • None.

June 3, 2025

Amsterdam, the Netherlands – argenx (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, today announced that Karl Gubitz, Chief Financial Officer, will participate in a fireside chat at the Goldman Sachs 46th Annual Global Healthcare Conference on Tuesday, June 10, 2025 at 8:40 AM ET in Miami, FL.

A live webcast of the presentation may be accessed on the Investors section of the argenx website at argenx.com/investors. A replay of the webcast will be available on the argenx website for approximately 30 days following the presentation.

About argenx

argenx is a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases. Partnering with leading academic researchers through its Immunology Innovation Program (IIP), argenx aims to translate immunology breakthroughs into a world-class portfolio of novel antibody-based medicines. argenx developed and is commercializing the first approved neonatal Fc receptor (FcRn) blocker and is evaluating its broad potential in multiple serious autoimmune diseases while advancing several earlier stage experimental medicines within its therapeutic franchises. For more information, visit www.argenx.com and follow us on LinkedInInstagramFacebook, and YouTube.

Contacts

Media:

Ben Petok
bpetok@argenx.com

Investors:

Alexandra Roy
aroy@argenx.com


FAQ

When is argenx (ARGX) presenting at the Goldman Sachs Healthcare Conference 2025?

argenx will present at the Goldman Sachs Healthcare Conference on Tuesday, June 10, 2025 at 8:40 AM ET in Miami, FL.

Who will represent argenx (ARGX) at the Goldman Sachs Healthcare Conference 2025?

Karl Gubitz, Chief Financial Officer of argenx, will participate in a fireside chat at the conference.

How can I watch argenx's (ARGX) presentation at the Goldman Sachs Healthcare Conference?

The presentation can be accessed via live webcast through the Investors section of argenx's website at argenx.com/investors.

How long will argenx's (ARGX) Goldman Sachs Conference presentation replay be available?

A replay of the webcast will be available on the argenx website for approximately 30 days following the presentation.
Argenx Se

NASDAQ:ARGX

ARGX Rankings

ARGX Latest News

ARGX Stock Data

35.40B
60.72M
0%
57.9%
3.28%
Biotechnology
Healthcare
Link
Netherlands
Amsterdam